Aldose reductase inhibitors: 2013-present

References

• Kador PF. The role of aldose reductase in the development of diabetic complications. Med Res Rev. 1988;8: 325–352.
   PubMed Web of Science ®Google Scholar
• Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev. 1998;50:21–33.
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
   PubMed Web of Science ®Google Scholar
• Wiernsperger NF. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Diabetes Metab. 2003;29:579–585.
   PubMed Web of Science ®Google Scholar
• Purves T, Middlemas A, Agthon S, et al. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J. 2001;15:2508–2514.
   PubMed Web of Science ®Google Scholar
• Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42:801–813.
   PubMed Web of Science ®Google Scholar
• Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol. 2012;3:1–8.
   PubMed Web of Science ®Google Scholar
• Obrosova IG. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signaling. 2005;7:1543–1552.
   PubMed Web of Science ®Google Scholar
• Demaine AG. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr Med Chem. 2003;10:1389–1398.
   PubMed Web of Science ®Google Scholar
• Zhao HL, Tong PC, Lai FM, et al. Association of glomerulopathy with the 5ʹ-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients. Diabetes. 2004;53:2984–2991.
   PubMed Web of Science ®Google Scholar
• Thamotharampillai K, Chan AK, Bennetts B, et al. Decline in neurophysiological function after 7 years in an adolescent diabetic cohort and the role of aldose reductase gene polymorphisms. Diabetes Care. 2006;29:2053–2057.
   PubMed Web of Science ®Google Scholar
• Chung SS, Chung SK. Genetic analysis of aldose reductase in diabetic complications. Curr Med Chem. 2003;10: 1375–1387.
   PubMed Web of Science ®Google Scholar
• Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Invest Drugs. 1999;8:2095–2119.
   PubMedGoogle Scholar
• Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets. 2008;9:14–36.
   PubMed Web of Science ®Google Scholar
• http://www.scifinder.cas.org.
   Google Scholar
• Li QR, Wang Z, Zhou W, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway. Neural Regen Res. 2016;11:345–351.
   PubMed Web of Science ®Google Scholar
• Sarges R, Schnur RC, Belletire JL, et al. Spirohydantoin aldose reductase inhibitor. J Med Chem. 1988;31:230–243.
   PubMed Web of Science ®Google Scholar
• Sestanj K, Bellini F, Fung S, et al. N-[[5-(Trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. J Med Chem. 1984;27:255–256.
   PubMed Web of Science ®Google Scholar
• Mylari BL, Larson ER, Beyer TA, et al. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazine-acetic acid (Zopolrestat) and congeners. J Med Chem. 1991;34:108–122.
   PubMed Web of Science ®Google Scholar
• Sladek NE. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol. 2003;17:7–23.
   PubMed Web of Science ®Google Scholar
• Vasiliou V, Pappa A, Estey T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev. 2004;36:279–299.
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Singhal SS, Bajpai KK, et al. A group of novel glutathione S-transferase isozymes showing high activity towards 4-hydroxy-2-nonenal are present in bovine ocular tissues. Exp Eye Res. 1994;59:151–159.
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Singhal SS, Awasthi S, et al. A glutathione S-transferases isozyme (bGST 5.8) involved in the metabolism of 4-hydroxy-2-trans-nonenal is localized in bovine lens epithelium. Exp Eye Res. 1996;63:329–337.
   PubMed Web of Science ®Google Scholar
• Bohren KM, Bullock B, Wermuth B, et al. The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J Biol Chem. 1989;264:9547–9551.
   PubMed Web of Science ®Google Scholar
• El-Kabbani O, Wilson DK, Petrash JM, et al. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. Mol Vis. 1998;4:19–25.
   PubMedGoogle Scholar
• Petrash JM. All in the family: aldose reductase and closely related aldo-keto reductases. Cell Mol Life Sci. 2004;61: 737–749.
   PubMed Web of Science ®Google Scholar
• El-Kabbani O, Ruiz F, Darmanin C, et al. Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci. 2004;61:750–762.
   PubMed Web of Science ®Google Scholar
• El-Kabbani O, Podjarny A. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. Cell Mol Life Sci. 2007;64:1970–1978.
   PubMed Web of Science ®Google Scholar
• Alexiou P, Pegklidou K, Chatzopoulou M, et al. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem. 2009;16:734–752.
   PubMed Web of Science ®Google Scholar
• Ramana KV, Srivastava SK. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol. 2010;42: 17–20.
   PubMed Web of Science ®Google Scholar
• Ramana KV. Aldose reductase: new insights for an old enzyme. Biomol Concepts. 2011;2:103–114.
   PubMedGoogle Scholar
• Borhani DW, Harter TM, Petrash JM. The crystal structure of the aldose reductase.NADPH binary complex. J Biol Chem. 1992;267:24871–24877.
   PubMed Web of Science ®Google Scholar
• Wilson DK, Bohren KM, Gabbay KH, et al. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science. 1992;257:81–84.
   PubMed Web of Science ®Google Scholar
• Rondeau JM, Tete Favier F, Podjarny A, et al. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature. 1992;355:469–472.
   PubMed Web of Science ®Google Scholar
• El-Kabbani O, Judge K, Ginell S, et al. Structure of porcine aldehyde reductase holoenzyme. Nat Struct Biol. 1995;2:687–692.
   PubMedGoogle Scholar
• Kinoshita JH, Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev. 1988;4:323–337.
   PubMed Web of Science ®Google Scholar
• Bhatnagar A, Srivastava SK. Aldose reductase: congenial and injurious profiles of an enigmatic enzyme. Biochem Med Metab Biol. 1992;48:91–121.
   PubMedGoogle Scholar
• Kubiseski TJ, Flynn TG. Studies on human aldose reductase. Probing the role of arginine 268 by site-directed mutagenesis. J Biol Chem. 1995;270:16911–16917.
   PubMed Web of Science ®Google Scholar
• Vander Jagt DL, Kolb NS, Vander Jagt TJ, et al. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta. 1995;1249:117–126.
   PubMed Web of Science ®Google Scholar
• Ramana KV, Dixit BL, Srivastava S, et al. Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry. 2000;39:12172–12180.
   PubMed Web of Science ®Google Scholar
• Dixit BL, Balendiran GK, Watowich SJ, et al. Kinetic and structural characterization of the Glutathione-binding Site of Aldose Reductase. J Biol Chem. 2000;275:21587–21595.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Liu SQ, Conklin DJ, et al. Involvement of aldose reductase in the metabolism of atherogenic aldehydes. Chem Biol Interact. 2001;130–132:563–571.
   PubMed Web of Science ®Google Scholar
• Chang KC, Paek KS, Kim HJ, et al. Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. Mol Pharmacol. 2002;61:1184–1191.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Spite M, Trent JO, et al. Aldose reductase-catalyzed reduction of aldehyde phospholipids. J Biol Chem. 2004;279:53395–53406.
   PubMed Web of Science ®Google Scholar
• Singh R, White MA, Ramana KV, et al. Structure of a glutathione conjugate bound to the active site of aldose reductase. Proteins Struct Func Bioinf. 2006;64:101–110.
   PubMed Web of Science ®Google Scholar
• Spite M, Baba SP, Ahmed Y, et al. Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochemical J. 2007;405:95–105.
   PubMed Web of Science ®Google Scholar
• Hohman TC, El-Kabbani O, Malamas MS, et al. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis. Eur J Biochem. 1998;256:310–316.
   PubMedGoogle Scholar
• Sotriffer CA, Krämer O, Klebe G. Probing flexibility and “induced-fit” phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Proteins. 2004;56: 52–66.
   PubMed Web of Science ®Google Scholar
• Podjarny A, Cachau RE, Schneider T, et al. Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding. Cell Mol Life Sci. 2004;61:763–773.
   PubMed Web of Science ®Google Scholar
• Harrison DH, Bohren KM, Ringe D, et al. An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate. Biochemistry. 1994;33:2011–2020.
   PubMed Web of Science ®Google Scholar
• Urzhumtsev A, Tête-Favier F, Mitschler A, et al. A ‘specificity’ pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure. 1997;5:601–612.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Miyake H, Fujii T, et al. The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat. Acta Crystallogr D Biol Crystallogr. 2002;58:622–626.
   PubMed Web of Science ®Google Scholar
• Howard EI, Sanishvili R, Cachau RE, et al. A.Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A. Proteins. 2004;55:792–804.
   PubMed Web of Science ®Google Scholar
• Steuber H, Zentgraf M, La Motta C, et al. Evidence for a novel binding site conformer of aldose reductase in ligand bound-state. J Mol Biol. 2007;369:186–197.
   PubMed Web of Science ®Google Scholar
• Zentgraf M, Steuber H, Koch C, et al. How reliable are current docking approaches for structure-based drug design? Angew Chem Int Ed Engl. 2007;46:3575–3578.
   PubMed Web of Science ®Google Scholar
• Klebe G, Kraemer O, Sotriffer C. Strategies for the design of inhibitors of aldose reductase, an enzyme showing pronounced induced fit adaptations. Cell Mol Life Sci. 2004;61:783–793.
   PubMed Web of Science ®Google Scholar
• Kraemer O, Hazemann I, Podjarny AD, et al. Virtual screening for inhibitors of human aldose reductase. Proteins. 2004;55:814–823.
   PubMed Web of Science ®Google Scholar
• Nencetti S, La Motta C, Rossello A, et al. N-(Aroyl)-N-(arylmethyloxy)-α-alanines: selective inhibitors of aldose reductase. Bioorg Med Chem. 2017;25:3068–3076.
   PubMed Web of Science ®Google Scholar
• El-Sayed S, Metwally K, El-Shanawani AA, et al. Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: synthesis, functional evaluation and molecular modeling study. Bioorg Med Chem Lett. 2017;27:4760–4764.
   PubMed Web of Science ®Google Scholar
• Sartini S, Cosconati S, Marinelli L, et al. Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies. J Med Chem. 2012;55:10523–10531.
   PubMed Web of Science ®Google Scholar
• Ramunno A, Cosconati S, Sartini S, et al. Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step. Eur J Med Chem. 2012;51:216–226.
   PubMed Web of Science ®Google Scholar
• Ottanà R, Maccari R, Giglio M, et al. Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. Eur J Med Chem. 2011;46:2797–2806.
   PubMed Web of Science ®Google Scholar
• Cosconati S, Marinelli L, La Motta C, et al. Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening. J Med Chem. 2009;52:5578–5581.
   PubMed Web of Science ®Google Scholar
• La Motta C, Sartini S, Salerno S, et al. Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model. J Med Chem. 2008;51:3182–3193.
   PubMed Web of Science ®Google Scholar
• La Motta C, Sartini S, Mugnaini L, et al. Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity. J Med Chem. 2007;50:4917–4927.
   PubMed Web of Science ®Google Scholar
• Da Settimo C, Primofiore G, La Motta C, et al. Naphtho[1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors. J Med Chem. 2005;48:6897–6907.
   PubMed Web of Science ®Google Scholar
• Da Settimo F, Primofiore G, La Motta C, et al. Spirohydantoin derivatives of thiopyrano[2,3-b]pyridin-4(4H)-one as potent in vitro and in vivo aldose reductase inhibitors. Bioorg Med Chem. 2005;13:491–499.
   PubMed Web of Science ®Google Scholar
• Da Settimo F, Primofiore G, Da Settimo A, et al. Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives. J Med Chem. 2003;46:1419–1428.
   PubMed Web of Science ®Google Scholar
• Da Settimo F, Primofiore G, Da Settimo A, et al. [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors. J Med Chem. 2001;44:4359–4369.
   PubMedGoogle Scholar
• World Health Organization. WHO traditional medicine strategy: 2014–2023. Geneva: WHO Press; 2013.
   Google Scholar
• Del Corso A, Barsacchi D, Riannessi M, et al. Change in stereospecificity of bovine lens aldose reductase modified by oxidative stress. J Biol Chem. 1989;264:17653–17655.
   PubMed Web of Science ®Google Scholar
• Grimshaw CE, Lai CJ. Oxidized aldose reductase: in vivo factor not in vitro artifact. Arch Biochem Biophys. 1996;327:89–97.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim JH, Kim CS et al. Hedera rhombea extracts for the prevention and treatment of diabetic complications. Repub. Korean Kongkae Taeho Kongbo. KR2013049660, A20130514. 2013
   Google Scholar
• Lim SS, Baek JH, Lee SG Composition containing extract or fraction of Nardostachys chinensis and used for alleviating, preventing or treating diabetic complication. Repub. Korean Kongkae Taeho Kongbo. KR2015083375, A20150717. 2015.
   Google Scholar
• Lim SS, Seo HW, Lee SG et al. Colocasia esculenta extracts for preventing and treating diabetic complications. Repub. Korean Kongkae Taeho Kongbo. KR2015078693, A20150708. 2015.
   Google Scholar
• Lim SS, Kang IJ, Yoon GS et al. Syringa oblata extracts for the prevention and treatment of diabetes complications. Repub. Korean Kongkae Taeho Kongbo. KR2014084907, A20140707. 2014.
   Google Scholar
• Lee GW, Hong CU, Nam MH et al. Pheophorbide A for treating obesity, diabetes or diabetic complications. Repub. Korean Kongkae Taeho Kongbo. KR2014047247, A20140422. 2014.
   Google Scholar
• Lee SH, Mok SY Rhododendron mucronulatum albiflorum extracts for preventing and treating diabetes or diabetic complications. Repub. Korean Kongkae Taeho Kongbo. KR2013124740, A20131115. 2013.
   Google Scholar
• Chang HB, Yoon J, Lee H et al. Use of compounds isolated from Morus bark. PCT Int. Appl.. WO2014168458, A120141016. 2014.
   Google Scholar
• Zou X, Deng G, Peng S Application of theanine, tea polysaccharide and Rubus suavissimus extract as aldose reductase inhibitor. Faming Zhuanli Shenqing. CN103405467, A20131127. 2013.
   Google Scholar
• Liu H, Ma B, Yang B et al. Ganoderma meroterpenoid compound and pharmaceutical composition and application thereof. Faming Zhuanli Shenqing. CN107163009, A20170915. 2017.
   Google Scholar
• Liu H, Ma B, Yang B et al. Ganoderma triterpenoids compound isolated from Ganoderma lucidum as aldose reductase inhibitor. Faming Zhuanli Shenqing. CN107056867, A20170818. 2017.
   Google Scholar
• Zhang K, Zhou A, Ma Y et al. An aldose reductase inhibitor, its preparation method by extraction from Edgeworthia gardneri flowers and application in treating diabetic complications. Faming Zhuanli Shenqing. CN105687223, A20160622. 2016.
   Google Scholar
• Murai H, Shimoda H, Yoshikawa M et al. Aldose reductase inhibitor containing cherry extract. Jpn. Kokai Tokkyo Koho. JP2013224280, A20131031. 2013.
   Google Scholar
• Julius A Inhibition of aldose reductase by natural compounds (agnuside, eupalitin-3-o-galactoside, picroside ii and 7-o-methylwogonin) to treat diabetic retinopathy. Indian Pat. Appl.. IN2015CH04993, A20170630. 2017.
   Google Scholar
• Stefek M, Kovacikova L, Milackova I et al. Preparation of quercetin derivatives for use in treatment of diseases associated with oxidative stress or polyol pathway. PCT Int. Appl.. WO2013130020, A120130906. 2013.
   Google Scholar
• Chen H, Li Y, He R Preparation of α-cyano-4-hydroxycinnamic acid derivative and their application as aldose reductase inhibitor. Faming Zhuanli Shenqing. CN104447406, A20150325. 2015.
   Google Scholar
• Chen H, Li Y, He R et al. Preparation of α-cyano-4-hydroxycinnamic acid derivative and their application as aldose reductase inhibitor. PCT Int. Appl.. WO2016082798, A120160602. 2016.
   Google Scholar
• Chen H, Yuan S, Li Y et al. Preparation of cinnamic acid derivatives as aldose reductase inhibitors. Faming Zhuanli Shenqing. CN107082754, A20170822. 2017.
   Google Scholar
• Labarbera DV, Petrash MJ Compounds reducing the production of sorbitol in the eye and methods of using the same. U.S. Pat. Appl. Publ.. US20150197536, A120150716. 2015.
   Google Scholar
• Labarbera DV, Petrash J Mark Compounds reducing the production of sorbitol in the eye and methods of using the same. PCT Int. Appl.. WO2014022291, A120140206. 2014.
   Google Scholar
• Puppala M, Ponder J, Suryanarayana P, et al. The isolation and characterization of β-Glucogallin as a novel aldose reductase inhibitor from Emblica officinalis. PLoS ONE. 2012;7:e31399.
   PubMed Web of Science ®Google Scholar
• Wasmuth A, Landry DW, Deng SX et al. Preparation of oxodihydropyrazinopyridazine derivatives for use as aldose reductase inhibitors. U.S. Pat. Appl. Publ.. US20130225592, A120130829. 2013.
   Google Scholar
• Wasmuth A, Landry DW, Deng SX et al. Preparation of oxodihydropyrazinopyridazine derivatives for use as aldose reductase inhibitors. PCT Int. Appl.. WO2014113380, A120140724. 2014.
   Google Scholar
• Mylari BL Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications. U.S. Pat. Appl. Publ.. US20140228319, A120140814. 2014.
   Google Scholar
• Mylari BL Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications. PCT Int. Appl.. WO2014126885, A120140821. 2014.
   Google Scholar
• Shendelman S Aldose reductase inhibitors such as boronic acid and boronate ester compounds and uses thereof. PCT Int. Appl.. WO2018200258, A120181101. 2018.
   Google Scholar
• Wasmuth A, Landry DW Aldose reductase inhibitors and methods of use thereof. PCT Int. Appl.. WO2017223179, A120171228. 2017.
   Google Scholar
• Stefek M, Milackova I, Diez-Dacal B et al. Use of 5-carboxymethyl-3-mercapto-1,2,4-triazino-[5,6-b]indoles and pharmaceutical preparation containing them. Slovakia. SK288508, B620171003. 2017.
   Google Scholar
• Stefek M, Milackova I, Diez-Dacal B et al. Use of 5-carboxymethyl-3-mercapto-1,2,4-triazino-[5,6-b]indoles and their pharmaceutical composition. PCT Int. Appl.. WO2015057175, A120150423. 2015.
   Google Scholar
• Laffin B, Petrash JM. Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers. Front Pharmacol. 2012;3:104.
   PubMed Web of Science ®Google Scholar
• Liu M, Xu L, Piao L et al. Application of piperazine compound. Faming Zhuanli Shenqing. CN107669682, A20180209. 2018.
   Google Scholar
• Liu M, Xu L, Huo X et al. Application of piperidine compound in preparation of drugs for treating cancers related to AKR1B10 or AKR1B1. Faming Zhuanli Shenqing. CN107595846, A20180119. 2018.
   Google Scholar
• Xu L, Liu M, Sun L et al. Application of coumarin derivative. Faming Zhuanli Shenqing. CN107485611, A20171219. 2017.
   Google Scholar
• Xu L, Liu M, Xu P et al. New application of 6-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-3-phenyl-[1,2,4]triazolo[4,3-b]pyridazine in preparation of medicine for treatment of AKR1B10 related cancer. Faming Zhuanli Shenqing. CN107375292, A20171124. 2017.
   Google Scholar
• Cappiello M, Da Settimo F, Del Corso A et al. New type of aldose reductase inhibitor. Italy. IT1410386, B120140909. 2014.
   Google Scholar
• Purushottam AY, Yogesh AM, Kumar GA et al. 2,4-Thiazolidinedione derivatives as aldose reductase inhibitors and PPAR agonists, and their preparation and use for the treatment of diabetes mellitus Indian Pat. Appl.. IN2013MU02615, A20140815. 2014.
   Google Scholar
• Xiu Z, Song Y, Zhao C et al. Preparation method of 5-phenylpyrrole derivative, and its use as an aldose reductase inhibitor. Faming Zhuanli Shenqing. CN107892666, A20180410. 2018.
   Google Scholar
• Alvarez Rivera F, Concheiro Nine A, Alvarez Lorenzo C Hydrogels for administering drugs that are aldose reductase inhibitors. Span.. ES2604196, A120170303. 2017.
   Google Scholar
• Alvarez Rivera F, Concheiro Nine A, Alvarez Lorenso C Hydrogels for administering drugs that are aldose reductase inhibitors. PCT Int. Appl.. WO2018134467, A120180726. 2018.
   Google Scholar
• Wyman M, Bellavia V Composition for treating ocular effects of diabetes comprising an aldose reductase inhibitor. U.S. Pat. Appl. Publ.. US20150057323, A120150226. 2015.
   Google Scholar
• Wyman M, Bellavia V Composition for treating ocular effects of diabetes comprising an aldose reductase inhibitor. PCT Int. Appl.. WO2015026380, A120150226. 2015.
   Google Scholar
• Srivastava SK, Ramana KV Compositions and methods for treating colon cancer using an aldose reductase specific inhibitor. U.S. Pat. Appl. Publ.. US20140206693, A120140724. 2014.
   Google Scholar